Imagion Biosystems Ltd. (AU:IBX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imagion Biosystems Ltd. is set to boost its MagSense® molecular MRI imaging technology, supported by a $3 million capital raise. The funds will advance clinical development, including a Phase 2 study for its HER2 imaging agent, and extend its technology to prostate and ovarian cancer detection. The company also welcomes Dr. Susan Harvey as a new Medical Affairs Advisor, enhancing its expertise in cancer imaging.
For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.